The new incretin-based therapies, dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon
like peptide 1 (GLP1) receptor agonists are widely used for the treatment of type 2 diabetes …

Objectives: Aggressive invasion and early metastases are characteristic features of
pancreatic ductal adenocarcinoma (PDAC). More than 90% of patients have surgically …

Background: Insulin resistance is a pathological condition characterized by the failure of
target cells to uptake and metabolize glucose in response to insulin. In particular, the …

Regardless of advances in detection and treatment, breast cancer affects about 1.5 million
women all over the world. Since the last decade, genome-wide association studies (GWAS) …

MicroRNAs, short non-coding regulators of the gene expression, are subjects of numerous
investigations assessing their potential use in the diagnostics and management of human …

Glucagon like peptide 1 (GLP1) is an incretin hormone released from the enteroendocrine L-
type cells of the lower gastrointestinal tract. The active isoforms of GLP1 are rapidly …

Pancreatic cancer remains a disease with very poor prognosis (only 5-6% of patients are still
alive after five years). Attempts to improve the results of treatment of pancreatic cancer focus …

Objectives MicroRNAs are molecules implicated in RNA-RNA interaction, playing a role in
cell proliferation and differentiation, as well as in carcinogenesis. Knowledge on their …

Simple Summary The most common form of endocrine cancer-papillary thyroid carcinoma,
has an increasing incidence. Although this disease usually has an indolent behavior, there …

Despite tremendous efforts from scientists and clinicians worldwide, pancreatic
adenocarcinoma (PDAC) remains a deadly disease due to the lack of early diagnostic tools …